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Abstract
There is little doubt that significant benefits can accrue from carrying out screening mammography
of women aged 40–49 in the setting of a highly quality assured service delivery. This will best be
achieved using digital mammography to maximise detection rates and trained and high volume
reading expert radiologists to apply economic cushions of optimising specificity as well as sensitivity
in addition to utilising modern and accurate assessment and tissue sampling techniques that have
evolved.
Article
The National Health Service Breast Screening Programme
(NHSBSP) in the UK routinely invites women aged 50–70
years for mammographic screening on a 3 yearly basis.
However debates have been underway for many years as
to whether or not extending screening to include women
age 40–49 should be considered. The age of 50 was cho-
sen as a surrogate for the menopause and because of the
rising incidence of breast cancer at this age, but there is lit-
tle data to support this as the ideal start age for mammo-
graphic screening[1]. Post-menopausal breast tissue
involutes and mammographic abnormalities are easier to
detect than in pre-menopausal breasts, but with women
reaching the menopause from their 30's to their 60's, the
advent of hormone replacement therapy (HRT) use in
post-menopausal women, and with the advent of digital
mammography, this feature diminishes and so the argu-
ment for commencing screening at 50 is weakened.
In 1997 a meta-analysis of all eight randomised control-
led trials (RCTs) which included data on breast screening
in women under 50 concluded that there was a statisti-
cally significant 18% reduction in breast cancer mortality
in women aged 40–49 who were mammographically
screened compared to the controls[2]. However, these
RCTs were performed from 1963 to 1982, and since then
there have been many improvements in technology, such
as the introduction of full field digital mammography,
and in the expertise of radiologists in interpreting mam-
mograms. It is beyond reasonable doubt therefore that
this reduction in mortality of 18% could be substantially
improved upon today.
The only randomised study to investigate this issue since
the meta-analysis in 1997 is the UK study. This study was
set up in 1991 to study the effects of mammography spe-
cifically for women aged 40–41 with annual mammo-
grams. Screening in the trial was by two-view
mammography at the first screen, with single view there-
after. Interim results published in 2005 show that screen-
ing has identified an increase of 8% of invasive cancers,
and predicted that deaths at 10 years are 10–11% less than
the control group[3]. However, this figure will probably
increase with continued follow-up as it is known that the
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improvement in mortality for younger women screened
improves with length of follow up. The meta-analysis
mentioned above showed that at 7 years of follow up,
there was no mortality reduction for younger women, but
at 10.4 years a non-significant improvement of 16% was
found, and at 12.4 years, the benefit had risen to statisti-
cally significant 18%[2]. Beyond RCTs, and with a specific
reference to the 40–49 group, Tabar et al showed that after
a 20 year follow up of implementation of service screen-
ing in the Swedish Two-Counties, there was a significant
48% reduction in breast cancer mortality for the screening
group-and a non-significant 19% reduction in unscreened
women[4]. Such results demonstrate the need for high
quality, specialisation and a small number of expert cen-
tres being involved.
The UK study reported lower than expected detection rates
and this can be partly attributed to the use of single-view
rather than two-view mammography for incident screens,
and the fact that early contributors were not working to
the mammographic standards (such as optical density)
that we now regard as acceptable and which showed a sig-
nificant improvement over the second half of the trial
period.
In addition to the potential reduction in mortality, screen-
ing mammography also leads to benefits in tumour char-
acteristics and eligibility for conservative surgery and less
toxic systemic therapy thus leading to a better quality of
life[4]. It is known that increasing size and stage of breast
cancer is associated with more toxic treatment and poorer
cosmetic outcome[5,6]. Studies show that breast cancers
diagnosed by screening mammography are of smaller
size, at an earlier stage and show more favourable nodal
status compared to non-screening detected cancers[7-11].
The Gothenberg breast screening trial showed that the
effects of invitation to screening on the incidence of
lymph node positive disease closely paralleled the benefi-
cial effects of invitation on breast cancer mortality[12].
With strong evidence that breast conserving surgery is a
safe alternative to mastectomy, screen detection of cancer
allows women the option of breast conserving surgery and
minimally invasive axillary surgery as an alternative to
mastectomy and axillary node clearance.
Should mammography be introduced to women under
50, then the current 3 yearly invitation is too infrequent to
be effective. While DCIS currently accounts for 20% of all
screen-detected cancers, the aggressive cancers that occur
in younger women need to be detected early to allow ben-
efits of screening and treatment. A Swedish study showed
that the two yearly screening interval was not effective in
detecting the more aggressive tumours with poor progno-
sis. The authors concluded that women under 50 should
have mammograms every 12–18 months to gain most
benefit from screening[13,14]. Moreover, a recent Ameri-
can study demonstrated that women with breast cancer
were diagnosed with DCIS and earlier stage invasive dis-
ease more frequently if they had mammography at least
annually than if they had mammograms less fre-
quently[7].
X-ray screening programmes are obviously not without
risks!. The potentially harmful consequences of mammo-
graphic screening include lead time effect, radiation expo-
sure, false positive results and over-diagnosis of breast
disease[15]. For a screening programme to be acceptable,
the risks must be outweighed by the benefits. Critics of
breast screening programmes for younger women argue
that the extra radiation exposure is unacceptable for
denser, pre-menopausal breasts. However, it has been
found that the significant factor for the dose of radiation
in screening is not age, but the size of the breast and the
quality of the radiological equipment[16]. A study group
in 2005 set up a radiation risk model to estimate the
number of radiation-induced deaths, and assess the over-
all balance of lives saved by screening and deaths caused
by radiation exposure for women aged 20, 30 and 40. For
women under 40, the risks of regular mammograms out-
weighed the benefit of screening, but for women over 40,
annual 2 view mammography was deemed beneficial if
screening conveys a 20% mortality improvement. If the
perceived reduction in mortality is only 10%, then the
risk:benenfit ratio is zero[17]. Therefore, if conclusive evi-
dence can be found that the improvement in mortality
from screening is anything above 10% then the radiation
risk will be outweighed by the benefits of breast cancer
screening for women over 40. However such estimates
have been based on the use of film mammography rather
than full-field digital mammography which has a higher
accuracy and allows a lower radiation dose to be used[18].
Another argument against screening in younger women is
the decreased sensitivity of mammography in the younger
age group. While the sensitivity of film mammography is
poorer for younger women, a recent multi-centre study
involving a total of 49,528 asymptomatic women present-
ing for screening showed that digital mammography was
more accurate than film mammography in women under
50, and those with dense, pre- or peri-menopausal
breasts[18]. Therefore along with other imaging tech-
niques, such as ultrasound and magnetic resonance imag-
ing, accurate diagnosis of breast cancer can be improved
further with modern imaging techniques.
Investigation of suspicious mammographic findings must
include a tissue diagnosis to either identify the type of
malignancy, or exclude its presence. For screening
patients, the lesions are often impalpable, and in previous
years, open surgical biopsy was often performed for tissueInternational Seminars in Surgical Oncology 2006, 3:4 http://www.issoonline.com/content/3/1/4
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diagnosis. For false positive mammograms, this meant
that women were exposed to unnecessary surgical proce-
dures. However, the use of ultrasound guided and stereo-
tactic core biopsies has meant that most of the false
positive results from screening can now be diagnosed with
relatively non invasive procedures. A recent meta-analysis
and multi-institutional trial showed that stereotactic core
biopsy had a similar false negative rate (1–3%) to that of
wire guided open biopsy[19-21].
Anxiety associated with recall for suspicious mammo-
grams is a concern for screening groups of all ages. How-
ever studies have found that for women with normal or
benign results at recall, the distress is short lived and
diminishes with time[22]. It was also shown that there
was no evidence of long term anxiety or depression for the
majority of these women recalled with false positive
results[23]. Anxiety is highest in women awaiting surgical
biopsy, but with non surgical core biopsies and rapid
release of results of investigations, these anxieties should
not be long standing for these women. In one study, the
majority of women asked said that they were satisfied
with the screening programme despite the potential for
false positive results[24] and in another study, women
recalled for benign disease were almost unanimously con-
tent with participating in the breast cancer screening pro-
gramme[22].
Cost-effectiveness is a key issue in the NHSBSP as the inci-
dence is so much lower in this group and the difficulty of
finding trained staff to run yet another extension to the
programme might cause it to collapse. The additional
workload to the programme from adding this age group
would be over 80 % compared to the currently expanded
service and approximately 140% more than the original
Forrest specification. Nevertheless we are in a situation
where cancers in this age group are increasing and breast
cancer remains the single commonest cause of death
among women aged 35–50 and one third of life years lost
are to those women diagnosed in their 40 s. All this at a
time of arguably the greatest devastation to family and
economic life[25].
International opinion is changing regarding the recom-
mendations for mammography in women under the age
of 50. By informing women of the potential harms and
benefits of screening, they can make their own choices as
to the age at which they start screening programmes. In
one study, when pros and cons of screening were
explained to women, the majority opted for screening
[26]. The American Association of Family Physicians, the
Canadian Task Force for Preventive Health, the American
Medical Association, the American Cancer Society and the
US Preventive Services Task Force all support mammogra-
phy screening beginning at age 40 with appropriate coun-
selling.
In conclusion, there is little doubt that significant benefits
can accrue from carrying out screening mammography of
women aged 40–49 in the setting of a high quality assured
service delivery. This will be best achieved using digital
mammography to maximise detection rates and trained
and high volume reading expert radiologists to apply eco-
nomic cushions of optimising specificity as well as sensi-
tivity in addition to utilising modern and accurate
assessment and tissue sampling that have evolved.
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